Sino Biopharmaceutical
Sino Biopharmaceutical
Sino Biopharmaceutical is a leading Chinese innovative research and R&D-driven pharmaceutical group
Sino Biopharmaceutical, founded in 2020 and headquartered in Hong Kong, is the leading innovative research and R&D-driven pharmaceutical group in China, with a business scope that covers the entire industry chain of pharmaceutical R&D platforms, intelligent production, and strong sales systems. Established by Xie Qirun, it was listed on the Hong Kong Stock Exchange In September of the same year as the foundation. The company's major shareholders are Thousand Eagles Limited, FRANCE INVESTMENT (CHINA 1) GROUP LIMITED, Remarkable Industries Limited, and Validated Profits Limited. Rivals with the direct and indirect competition with Sino Biopharmaceutical include Lansen Pharmaceutical, Chia Tai Enterprises, Hansoh Pharma.
- All
- News
- Analysis
- Research
Briefing Feb 07, 2023 12:11 PM
· Healthcare
ForLong Biotech Nets Over CNY 100 Mn in Series A
Briefing Feb 07, 2023 10:59 AM
· Healthcare
CytoCan Corp. Nets CNY 10 Mn in Seed Round
In-depth
Healthcare
Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis
‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’
Jan 30, 2023 02:13 PM
Briefing Jun 24, 2022 11:15 AM
· Healthcare
F-star to be acquired by China biopharmaceutical with USD 161million
Briefing Jun 24, 2022 11:07 AM
· Healthcare
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Research
Consumer Staples, Healthcare, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Briefing Jun 24, 2022 10:46 AM
· Healthcare
East China medicine "liraglutide" goes to sea
Briefing Jun 23, 2022 06:25 PM
· Healthcare
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Briefing Jun 23, 2022 06:24 PM
· Healthcare
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Briefing Jun 23, 2022 10:36 AM
· Healthcare
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Briefing Jun 23, 2022 10:27 AM
· Healthcare
Yanye new crown drug 3CL protein inhibitor has been suspended approval
Healthcare
CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM
There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?
Apr 27, 2022 09:45 PM
Briefing Apr 19, 2022 07:44 AM
· Healthcare
China biopharmaceutical: the fifth indication of anti-tumor drug "arotinib hydrochloride capsule" has been approved
Briefing Aug 18, 2021 07:54 PM
Jin Litai: the prices of various types of cathodic electrophoretic paint products rise by 10% - 20%
See more
Related Companies
